SLNO — Soleno Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.79bn
- $2.56bn
Annual cashflow statement for Soleno Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.6 | -30.9 | -24.1 | -39 | -176 |
| Depreciation | |||||
| Non-Cash Items | -5.51 | 2.33 | 2.08 | 9.16 | 98.7 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.98 | -1.15 | -0.756 | 2.93 | 6.02 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -25.2 | -27.8 | -20.8 | -24.9 | -69.1 |
| Capital Expenditures | -0.007 | -0.022 | -0.013 | 0 | -0.218 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | -225 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.007 | -0.022 | -0.013 | 0 | -226 |
| Financing Cash Flow Items | — | -0.12 | -1.06 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 53.7 | -0.128 | 14.1 | 180 | 213 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28.5 | -27.9 | -6.7 | 155 | -81.8 |